BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25194851)

  • 1. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
    Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
    World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
    Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
    J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.
    Cardoso AC; Beaugrand M; de Ledinghen V; Douvin C; Poupon R; Trinchet JC; Ziol M; Bedossa P; Marcellin P
    Ann Hepatol; 2015; 14(6):826-36. PubMed ID: 26436354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
    Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
    Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.
    Wang CY; Lu W; Hu DS; Wang GD; Cheng XJ
    World J Gastroenterol; 2014 Aug; 20(30):10585-90. PubMed ID: 25132779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
    Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
    Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
    Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
    Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
    Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
    World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
    Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic Steatosis in Chronic Hepatitis B as Measured by Controlled Attenuation Parameter: Frequency and Distribution.
    Nan S; Liang Y; Qu Y; Liu F; Wang L; Li T
    J Coll Physicians Surg Pak; 2019 Oct; 29(10):937-941. PubMed ID: 31564265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
    Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease.
    Shen F; Zheng RD; Shi JP; Mi YQ; Chen GF; Hu X; Liu YG; Wang XY; Pan Q; Chen GY; Chen JN; Xu L; Zhang RN; Xu LM; Fan JG
    Liver Int; 2015 Nov; 35(11):2392-400. PubMed ID: 25689614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.
    Semmler G; Stift J; Scheiner B; Wöran K; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Pinter M; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
    Dig Dis Sci; 2019 Dec; 64(12):3642-3651. PubMed ID: 31209721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.